Hallal David 4

What Happened

• David Hallal, a director of Kalaris Therapeutics, was granted a derivative award (option) covering 9,000 shares on June 3, 2026. The Form 4 reports an acquisition at $0.00 (no cash paid at grant). This is a grant/award (not a purchase or sale).

Key Details

• Transaction date: 2026-06-03; filing date: 2026-06-04 (timely).
• Transaction type/code: A (award/grant); derivative instrument (option) for 9,000 shares; reported price $0.00.
• Vesting: The option’s underlying shares vest in full on the earlier of (i) June 3, 2027 or (ii) the Issuer’s 2027 Annual Meeting of Stockholders, subject to continued service (per footnote F1).
• Shares owned after the transaction: not specified in the provided filing information.
• No indication of sale, exercise, tax-withholding, or 10b5-1 plan in this filing.

Context

• This was an equity compensation grant to a director, common for aligning executives/directors with shareholder interests. It does not represent an immediate purchase or sale and does not indicate any immediate change in Hallal’s net holdings until vesting/exercise occurs.